Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma.
adamantinoma). Case report and review of literature . J Cancer Res Clin Oncol 2008 ; 134 : 427 – 31 . Qureshi AA , Shott S , Mallin BA , Gitelis S . Current trends in the [2] management of adamantinoma of long bones. An international study . J Bone Joint Surg Am 2000 ; 82-A : 1122 – 31 . Hazelbag HM , Taminiau AH , Fleuren GJ , Hogendoorn PC . [3] Adamantinoma of the long bones. A clinicopathological study of thirty-two patients with emphasis on histological subtype, precursor lesion, and biological behavior . J Bone Joint Surg Am 1994 ; 76 : 1482 – 99 . Lokich J . Metastatic adamantinoma of bone to lung. A case [4] report of the natural history and the use of chemotherapy and radiation therapy . Am J Clin Oncol 1994 ; 17 : 157 – 9 . Dudek AZ , Murthaiah PK , Franklin M , Truskinovsky AM . [5] Metastatic adamantinoma responds to treatment with receptor tyrosine kinase inhibitor . Acta Oncol 2010 ; 49 : 101 – 4 . Van Der Graaf WT , Blay JY , Chawla SP , Kim DW , Bui-Nguyen [6] B , Casali PG , et al . Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebocontrolled phase 3 trial . Lancet 2012 ; 379 : 1879 – 86 . Motzer R , Hutson TE , Reeves J , Hawkins R , Guo J , Nathan [7] P , et al . Randomized, open-label, phase III trial of pazopanib versus sunitinib in fi rst-line treatment of patients with metastatic renal cell carcinoma (MRCC): Results of the COMPARZ trial. 37th ESMO Congress ; 2012 Sep 28 – Oct 2 ; Vienna, Austria . ing to manufacturer instructions). The cancer panel also included SMARCB1, a gene that when mutated is associated with hypersensitivity to pazopanib in cell cultures (see the ‘ Genomics of Drug Sensitivity in Cancer ’ database; (http://www.cancerrxgene.org/translation/Drug/199); this, however, was also found to be un-mutated. We suggest that treatment with pazopanib should be considered in the setting of metastatic AD. Further molecular profi ling of AD may identify the specifi c pathway and shed light on the mechanisms involved in sensitivity to pazopanib.